Autolus Therapeutics : Corporate Presentation – January 2021

Nasdaq: AUTL

Developing Next Generation Programmed T Cell Therapies

January 2021

Disclaimer

These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the "safe harbor" provisions of The Private Securities Litigation Reform Act of 1995, including statements about the safety, therapeutic potential and commercial opportunity of AUTO1 and AUTO3 and the future clinical development of AUTO1 and AUTO3 including progress, expectations as to the reporting of data, conduct and timing; the Company's plans to develop and commercialize its other product candidates and next generation programs including statements regarding the timing of initiation, completion of enrollment and availability of data from the Company's current preclinical studies and clinical trials; the Company's commercialization, marketing and manufacturing capabilities and strategy; the impact of the ongoing COVID- 19 pandemic on the Company's operations and clinical trials; and the restructuring program and Autolus' expected cash savings as a result of the restructuring program and operational changes. All statements other than statements of historical fact contained in this presentation, including statements regarding the Company's future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risks described in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019, as amended, as well as those set

forth from time to time in the Company's subsequent SEC filings, available at www.sec.gov. All information contained herein is as of the date of

the presentation, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing the Company's views as of any date subsequent to the date of this presentation.

Certain data in this presentation was obtained from various external sources. Such data speak only as of the date referenced in this presentation and neither the Company nor its affiliates, advisors or representatives make any representation as to the accuracy or

completeness of that data or undertake to update such data after the date of	this presentation. Such data involve risks and uncertainties and
are subject to change based on various factors.	2

Lead Clinical Programs

Striving for best-in-class therapies

3

Driving value with potential best-in-class adult ALL program

Focusing on delivering AUTO1, a potentially transformational treatment for Adult Acute Lymphoblastic Leukemia (ALL), as well as exploring activity in additional B-cell malignancies

Full data for AUTO1 - AL-1 study in adult expected in 2022

AUTO1 data in PCNSL and NHL expected in Q4 2021, AUTO1/22 in pALL expected in Q4 2021

o Plan to partner AUTO3 ahead of progressing into next phase of development

o Additional value steps in T cell lymphoma and first solid tumor indication

o Broad preclinical pipeline of next generation programs expected to transition to clinical stage in 2021/2022

o Scalable, fully enclosed manufacturing platform

4